Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AdoXLong Sema (Adocia)
- Development stage
- Preclinical
- Lead developer
- Adocia
- Modality
- Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
AdoXLong Sema is a long-acting injectable formulation of the GLP-1 receptor agonist semaglutide, developed by Adocia using its proprietary AdoXLong platform. The technology involves a biocompatible polymer chemically linked to the peptide, which extends the drug's half-life to allow for once-monthly subcutaneous administration instead of the standard weekly dosing. This formulation is designed as a low-viscosity aqueous solution compatible with standard 29 Gauge needles. It is currently in preclinical development, with proof-of-concept achieved for the treatment of obesity and type 2 diabetes.
- Other names
- AdoXLong semaglutide
02
Targets
Beyond the preview
Go deeper on AdoXLong Sema (Adocia).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AdoXLong Sema (Adocia).